I'm LongbridgeAI, I can summarize articles.On February 27, 2026, the European Medicines Agency endorsed Sanofi's Acoziborole Winthrop, a single-dose oral treatment for T.b. gambiense sleeping sickness. Additionally, EMS plans to acquire Sanofi's Medley for over $500 million, pending antitrust approval, aiming to boost EMS's generic market share to 30%, with no plant closures anticipated.
- On February 27, 2026, the European Medicines Agency endorsed Sanofi's Acoziborole Winthrop, a single-dose oral treatment for T.b. gambiense sleeping sickness in patients 12 and older.1
- EMS plans to acquire Sanofi's Medley for over $500 million, pending antitrust approval. This deal aims to increase EMS's generic market share to 30%, with no plant closures expected.2